FAKTOR OPTIONSSCHEIN - KODIAK SCIENCES Stock

Certificat

DE000GG6HN74

Real-time BOERSE MUENCHEN 06:26:07 2024-05-24 am EDT
0.75 EUR -18.03% Intraday chart for FAKTOR OPTIONSSCHEIN - KODIAK SCIENCES
Current month-35.11%
1 month-55.58%
Date Price Change
24-05-24 0.75 -18.03%
24-05-23 0.915 -10.03%
24-05-22 1.017 +17.17%
24-05-21 0.868 +14.97%
24-05-20 0.755 -40.92%

Real-time BOERSE MUENCHEN

Last update May 24, 2024 at 06:26 am EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying KODIAK SCIENCES INC.
Issuer Goldman Sachs
WKN GG6HN7
ISINDE000GG6HN74
Date issued 2024-04-04
Strike 2.488 $
Maturity Unlimited
Parity 0.63 : 1
Emission price 8.4
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.52
Lowest since issue 0.75
Spread 0.01
Spread %1.33%

Company Profile

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Sector
-
More about the company

Consensus: Kodiak Sciences Inc.

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3.11 USD
Average target price
4.25 USD
Spread / Average Target
+36.66%
Consensus